pharmexec.com
/1 month ago
Latest updates for Elicio
Fresh curated links around Elicio are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- <![CDATA[Elicio Therapeutics’ Shares Drop Following Announcement of Phase II Trial Results ]]>
- Elicio Therapeutics drops 5%, prices $15M direct offering
- Elixirgen Builds Rare Disease Pipeline Around Telomere Biology Disorders and DMD
Post angles to try
Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
genengnews.com
/1 week ago
Elixirgen Builds Rare Disease Pipeline Around Telomere Biology Disorders and DMD
Elixirgen's lead program is an ex vivo autologous therapy based on proprietary tech that targets telomere biology disorders, rare genetic diseases characterized by short telomeres...
newswire.com
/2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
newswire.com
/2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
newswire.com
/2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
qchron.com
/1 month ago
Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq
ARLINGTON, Mass., June 8, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) ("Eloxx" and the "Company"), a clinical-stage biopharmaceutical company developing novel,...
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.
Sources covering Elicio
feeds.feedburner.com
Recent coverage from public sources
Public source
seekingalpha.com
Recent coverage from public sources
Public source
newswire.com
Recent coverage from public sources
Public source
pharmexec.com
Recent coverage from public sources
Public source
qchron.com
Recent coverage from public sources
Public source